Morbidity and Mortality after Induction Chemotherapy Followed by Surgery in IIIa-N2 non Small Cell Lung Cancer

被引:1
|
作者
Borreman, Ph. [1 ]
De Leyn, P. [1 ]
Decaluwe, H. [1 ]
Moons, J. [1 ]
Van Raemdonck, D. [1 ]
Nafteux, Ph. [1 ]
Coosemans, W. [1 ]
Lerut, T. [1 ]
机构
[1] Katholieke Univ Leuven Hosp, Dept Thorac Surg, Louvain, Belgium
关键词
Lung cancer; non-small-cell carcinoma; chemotherapy; adjuvant; pneumonectomy; PROLONGED AIR LEAK; PREOPERATIVE CHEMOTHERAPY; PULMONARY LOBECTOMY; COMORBIDITY SCORE; RESECTION; COMPLICATIONS; SYSTEM; PREDICTORS; THERAPY; POSSUM;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective : To evaluate the frequency and risk of postoperative complications and mortality in patients with IIIa-N2 non small cell lung cancer after induction chemotherapy and surgery. Methods : In a surgical database records from ninety two patients, operated between January 1, 2000 and December 3 1, 2006 were reviewed. Univariate analysis was used to identify predictors of postoperative complications and in-hospital mortality. Results : All cases were histologically confirmed stage IIIa-N2. All patients received preoperative platinum based chemotherapy without radiotherapy. Pneumonectomy was performed in 20 cases (23.5%), from which 9 right sided. (Bi)lobectomy was performed in 53 cases (62.4%) and sleeve lobectomy in I I cases (17.2%). One wedge resection was performed (1.2%). In 7 cases (7.6%) only an exploration was done. Complications developed in 35 patients (38%). Major complications in 15 patients (16%). No bronchopleural fistulae were observed. Analysis identified increased age and high physiological and operative severity score for the enumeration of mortality and morbidity (POSSUM) as a risk factor to develop complications, and a high simplified comorbidity score as a risk factor to develop a major complication. Higher age, Charlson comorbidity index, simplified comorbidity score and POSSUM were a risk factor for developing pneumonia. Conclusion : Although surgery after induction therapy for IIIa-N2 NSCLC can be done with a morbidity and mortality comparable to surgery alone, it remains a high risk operation. It should therefore be performed in a center with experience. Bronchial stump protection should be used whenever there is an increased risk for developing a bronchopleural fistula. In deciding whether to do surgery or radiotherapy one should keep in mind the feasibility of performing a complete resection together with a preoperative assessment to predict complications and mortality. For the preoperative assessment several scoring systems can be used from which we find the simplified comorbidity score most useful.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 50 条
  • [31] Surgery as a Component of Multimodality Care for Known Stage IIIA-N2 Non-small Cell Lung Cancer
    Bograd, Adam J.
    Vallieres, Eric
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 41 (03) : 346 - 353
  • [32] Induction chemotherapy (± radiotherapy) followed by surgery in non-small cell lung cancer
    Quoix, E
    New Advances in Thoracic Oncology: From Scientific Evidence to Optimal Management, 2005, 350 : 169 - 175
  • [33] SURGERY FOR STAGE IIIA-N2 NONSMALL CELL LUNG-CANCER
    MOUNTAIN, CF
    CANCER, 1994, 73 (10) : 2589 - 2598
  • [34] Adjuvant Carboplatin-based Chemotherapy in Resected Stage IIIA-N2 Non-small Cell Lung Cancer
    Ou, Wei
    Sun, Hai-bo
    Ye, Xiong
    Zhang, Bin-bin
    Yang, Hua
    Fang, Qin
    Li, Pan
    Wang, Si-yu
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (07) : 1033 - 1041
  • [35] Risk Factor Analysis of Morbidity and 90-Day Mortality of Curative Resection in Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer after Induction Concurrent Chemoradiation Therapy
    Jeong, Ga Hee
    Lee, Junghee
    Jeon, Yeong Jeong
    Park, Seong Yong
    Kim, Hong Kwan
    Choi, Yong Soo
    Kim, Jhingook
    Shim, Young Mog
    Cho, Jong Ho
    JOURNAL OF CHEST SURGERY, 2024, 57 (04): : 351 - 359
  • [36] Interpretation and prognostic value of PET-CT after induction chemotherapy with or without radiation in IIIA-N2 non-small cell lung cancer patients who receive curative surgery
    Lee, J. H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Hyperfractionated Irradiation with 3 Cycles of Induction Chemotherapy in Stage IIIA-N2 Lung Cancer
    Fengshi Chen
    Kenichi Okubo
    Makoto Sonobe
    Keiko Shibuya
    Yukinori Matsuo
    Young Hak Kim
    Kazuhiro Yanagihara
    Toru Bando
    Hiroshi Date
    World Journal of Surgery, 2012, 36 : 2858 - 2864
  • [38] Hyperfractionated Irradiation with 3 Cycles of Induction Chemotherapy in Stage IIIA-N2 Lung Cancer
    Chen, Fengshi
    Okubo, Kenichi
    Sonobe, Makoto
    Shibuya, Keiko
    Matsuo, Yukinori
    Kim, Young Hak
    Yanagihara, Kazuhiro
    Bando, Toru
    Date, Hiroshi
    WORLD JOURNAL OF SURGERY, 2012, 36 (12) : 2858 - 2864
  • [39] Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: A prospective study
    Vansteenkiste, JF
    De Leyn, PR
    Deneffe, GJ
    Lievens, YN
    Nackaerts, KL
    Van Raemdonck, DE
    van der Schueren, E
    Lerut, TE
    Demedts, MG
    ANNALS OF ONCOLOGY, 1998, 9 (03) : 261 - 267
  • [40] Generalized or personalized treatment for stage IIIA-N2 non-small-cell lung cancer?
    Vansteenkiste, Johan
    Van Damme, Valerie
    Dooms, Christophe
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1605 - 1609